S&P 500   2,612.90 (+2.81%)
DOW   22,170.20 (+2.47%)
QQQ   191.31 (+3.24%)
AAPL   253.53 (+2.34%)
FB   164.88 (+5.16%)
MSFT   160.13 (+6.97%)
GOOGL   1,143.12 (+2.96%)
AMZN   1,951.96 (+2.73%)
NVDA   263.94 (+4.44%)
BABA   189.72 (+0.60%)
MU   44.29 (+2.22%)
GE   7.88 (+3.28%)
TSLA   505.84 (-1.66%)
AMD   47.92 (+2.88%)
T   30.04 (+0.67%)
ACB   0.88 (-14.52%)
F   5.03 (-3.27%)
NFLX   372.76 (+4.38%)
BAC   22.14 (+2.50%)
GILD   75.60 (+3.77%)
DIS   97.58 (+1.21%)
S&P 500   2,612.90 (+2.81%)
DOW   22,170.20 (+2.47%)
QQQ   191.31 (+3.24%)
AAPL   253.53 (+2.34%)
FB   164.88 (+5.16%)
MSFT   160.13 (+6.97%)
GOOGL   1,143.12 (+2.96%)
AMZN   1,951.96 (+2.73%)
NVDA   263.94 (+4.44%)
BABA   189.72 (+0.60%)
MU   44.29 (+2.22%)
GE   7.88 (+3.28%)
TSLA   505.84 (-1.66%)
AMD   47.92 (+2.88%)
T   30.04 (+0.67%)
ACB   0.88 (-14.52%)
F   5.03 (-3.27%)
NFLX   372.76 (+4.38%)
BAC   22.14 (+2.50%)
GILD   75.60 (+3.77%)
DIS   97.58 (+1.21%)
S&P 500   2,612.90 (+2.81%)
DOW   22,170.20 (+2.47%)
QQQ   191.31 (+3.24%)
AAPL   253.53 (+2.34%)
FB   164.88 (+5.16%)
MSFT   160.13 (+6.97%)
GOOGL   1,143.12 (+2.96%)
AMZN   1,951.96 (+2.73%)
NVDA   263.94 (+4.44%)
BABA   189.72 (+0.60%)
MU   44.29 (+2.22%)
GE   7.88 (+3.28%)
TSLA   505.84 (-1.66%)
AMD   47.92 (+2.88%)
T   30.04 (+0.67%)
ACB   0.88 (-14.52%)
F   5.03 (-3.27%)
NFLX   372.76 (+4.38%)
BAC   22.14 (+2.50%)
GILD   75.60 (+3.77%)
DIS   97.58 (+1.21%)
S&P 500   2,612.90 (+2.81%)
DOW   22,170.20 (+2.47%)
QQQ   191.31 (+3.24%)
AAPL   253.53 (+2.34%)
FB   164.88 (+5.16%)
MSFT   160.13 (+6.97%)
GOOGL   1,143.12 (+2.96%)
AMZN   1,951.96 (+2.73%)
NVDA   263.94 (+4.44%)
BABA   189.72 (+0.60%)
MU   44.29 (+2.22%)
GE   7.88 (+3.28%)
TSLA   505.84 (-1.66%)
AMD   47.92 (+2.88%)
T   30.04 (+0.67%)
ACB   0.88 (-14.52%)
F   5.03 (-3.27%)
NFLX   372.76 (+4.38%)
BAC   22.14 (+2.50%)
GILD   75.60 (+3.77%)
DIS   97.58 (+1.21%)
Log in

NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, Forecast & News

$1.98
+0.07 (+3.66 %)
(As of 03/30/2020 03:00 PM ET)
Today's Range
$1.90
Now: $1.98
$2.02
50-Day Range
$1.60
MA: $2.67
$4.11
52-Week Range
$1.38
Now: $1.98
$9.26
Volume3.83 million shs
Average Volume8.76 million shs
Market Capitalization$305.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
BioCryst Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.83 million
Book Value$0.26 per share

Profitability

Net Income$-108,900,000.00
Net Margins-222.99%

Miscellaneous

Employees100
Market Cap$305.30 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.


BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

How has BioCryst Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCRX shares have decreased by 23.4% and is now trading at $1.9850. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioCryst Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioCryst Pharmaceuticals.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for BioCryst Pharmaceuticals.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Thursday, March, 5th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.24. The biotechnology company had revenue of $39.73 million for the quarter, compared to analysts' expectations of $12.02 million. BioCryst Pharmaceuticals had a negative return on equity of 4,223.68% and a negative net margin of 222.99%. View BioCryst Pharmaceuticals' earnings history.

What price target have analysts set for BCRX?

8 Wall Street analysts have issued 1-year target prices for BioCryst Pharmaceuticals' shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $8.93 in the next twelve months. This suggests a possible upside of 349.8% from the stock's current price. View analysts' price targets for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (3/9/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to achievement of price target. We reiterate our Buy rating and our price target of $13 is based on the following risk-adjusted sum-of-the-parts NPV-DCF: $11.1 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.2 for peramivir + $0.4 in cash. We assume a discount rate of 13.5%." (5/22/2019)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

News stories about BCRX stock have trended very positive on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBioCryst Pharmaceuticals.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (6.34%), Point72 Asset Management L.P. (5.65%), State Street Corp (3.70%), UBS Group AG (3.70%), Sofinnova Investments Inc. (1.45%) and Jacobs Levy Equity Management Inc. (1.43%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan. View institutional ownership trends for BioCryst Pharmaceuticals.

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, FMR LLC, Public Sector Pension Investment Board, Rafferty Asset Management LLC, Janus Henderson Group PLC, Franklin Street Advisors Inc. NC, and Janney Montgomery Scott LLC. View insider buying and selling activity for BioCryst Pharmaceuticals.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., UBS Group AG, Sofinnova Investments Inc., Parkman Healthcare Partners LLC, State Street Corp, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., and Credit Suisse AG. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage. View insider buying and selling activity for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $1.99.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $306.07 million and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe. View additional information about BioCryst Pharmaceuticals.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is http://www.biocryst.com/.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  407 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  788
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel